Lipid panel — research review 2

...and this brings us to a really important point about human evidence versus the sheer volume of hype out there, especially concerning longevity. We see a lot of talk, but what are clinical trials actually showing?

Exactly. Take something like the lipid panel – your cholesterol and triglyceride profile. It's a standard biomarker, part of the 'biomarkers and biological age' pathway. We know high LDL cholesterol is a risk factor for cardiovascular disease.

Right, and interventions that effectively lower LDL, like statins, have strong clinical trial data demonstrating reduced cardiovascular events in specific populations. We're talking decades of research here. A large meta-analysis in The Lancet in 2010, for instance, showed clear benefits in primary and secondary prevention.

But what's fascinating is when we look beyond established treatments. There’s a constant stream of new supplements or dietary approaches claiming to 'optimize' lipid panels for longevity. Yet, many of these claims lack robust, large-scale human trials.

Precisely. Often, we see promising in vitro or animal studies, or even small observational human data. But when you put them to the test in a double-blind, placebo-controlled trial, the effect size is minimal, or sometimes, it’s a null result entirely.

And that null result is crucial! It means the intervention, despite the excitement, didn't show a statistically significant benefit in humans for that specific outcome. It doesn't mean it’s harmful, necessarily, but it certainly isn't proven beneficial.

So, while the lipid panel is an incredibly valuable tool for assessing cardiovascular risk, its direct utility for assessing 'biological age' or for guiding novel longevity interventions is still largely unproven for many of these newer approaches. We know what works for risk reduction, but the broader longevity connection for many emerging ideas remains a question mark.